Loading...
XNAS
OCGN
Market cap381mUSD
Dec 05, Last price  
1.22USD
1D
-1.61%
1Q
18.45%
Jan 2017
-26.95%
IPO
-89.00%
Name

Ocugen Inc

Chart & Performance

D1W1MN
XNAS:OCGN chart
P/E
—
P/S
93.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
81.15%
Rev. gr., 5y
%
Revenues
4m
-32.82%
26,0008,00000000042,62002,488,0006,036,0004,055,000
Net income
-54m
L-14.31%
-16,935,000-25,712,000-22,793,000-32,024,000-16,208,000-26,414,000-8,643,000-21,225,593-22,623,468-58,365,000-77,834,000-63,078,000-54,054,000
CFO
-42m
L-32.09%
-12,232,000-15,282,000-18,405,000-30,034,000-25,736,000-23,020,000-15,777,000-16,893,281-14,708,730-47,941,000-60,079,000-62,054,000-42,142,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
URL
https://ocugen.com/
IPO date
Dec 03, 2014
Employees
84
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT